Watch on demand: Managing first relapse in myeloma, the potential role of daratumumab

The anti-CD38 mAb daratumumab (Darzalex) is the first new agent with a different mode of action against multiple myeloma to be recommended by the PBAC for 13 years. Watch as a panel of experts discuss its potential role in the treatment of myeloma patients at first relapse, and how its availability may influence current front ...

Already a member?

Login to keep reading.

© 2021 the limbic